

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/422,804	10/22/1999	EDWIN SOUTHERN	00263/PP/IR	6012		
75	90 07/13/2005	·	EXAMINER			
Wenderoth, Lind & Ponack			MARSCHEL, ARDIN H			
2033 K street N	.W					
Washington, D	C 20006		ART UNIT	PAPER NUMBER		
		•	1631			
•			DATE MAILED: 07/13/2005	DATE MAILED: 07/13/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application	Application No. Applicant(s)					
		09/422,804		SOUTHERN, EDWIN				
		Examiner		Art Unit	•			
		Ardin Marso	hel	1631				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
THE M - Extens after S - If the p - If NO p - Failure Any re	DRTENED STATUTORY PERIOD FOR REIMAILING DATE OF THIS COMMUNICATION is consistent of time may be available under the provisions of 37 CFR BIX (6) MONTHS from the mailing date of this communication. Deenod for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by stately received by the Office later than three months after the main difference of the provided patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no even reply within the statute riod will apply and will atute, cause the applic	t, however, may a reply be ti ory minimum of thirty (30) da expire SIX (6) MONTHS fron ation to become ABANDONI	mely filed ys will be considered timel n the mailing date of this c ED (35 U.S.C. § 133).				
Status								
1)🛛 🛚	Responsive to communication(s) filed on 23	3 April 2002.						
2a) <u></u> □ ·	This action is FINAL . 2b)⊠ T	his action is no	n-final.	•				
,—	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition	on of Claims	•	·					
5)	Claim(s) <u>17-99</u> is/are pending in the applicate a) Of the above claim(s) is/are with declaim(s) is/are with declaim(s) is/are allowed. Claim(s) <u>17-99</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and	drawn from cons						
Application	on Papers				•			
-	he specification is objected to by the Exam		.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
	he oath or declaration is objected to by the	·	- · ·	-				
Priority ur	nder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
Attachment(s)		·					
	of References Cited (PTO-892)	4) Interview Summary		-			
3) Informa	of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449 or PTO/SB/(No(s)/Mail Date	_	Paper No(s)/Mail D Notice of Informal F Other:		O-152)			

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

Art Unit: 1631

DETAILED ACTION

Due to the below summarized issues, the suspension, mailed 10/18/02, is hereby withdrawn.

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. Upon reconsideration, the following rejections and/or objections are newly applied. They constitute the complete set presently being applied to the instant application.

PRIOR ART

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 17-19, 21-24, 38, 40, 42, 43, 45-51, 63, 64, 66, 73, 75, 76, 79, 80, 89, 91-94, and 96-98 are rejected under 35 U.S.C. 102(e)(2) as being clearly anticipated by Stavrianopoulos et al. (P/N 4,994,373).

Example 1 in column 8 of the reference discloses the treatment of a glass support with a silane linker for covalent linkage of single stranded DNA, reasonably an oligonucleotide, thereto to form an array for hybridization usage. In column 8, lines 40-45, the description of "various" single stranded analytes, including mutated gene fragments as in instant claim 19, for such hybridization is reasonably interpreted as

Art Unit: 1631

being "different" oligonucleotides as instantly claimed. The depressions or wells are clearly known locations also as instantly claimed. It is well known that glass itself is impermeable as instantly required even though it may be macroscopically porous. Microtiter plates as utilized in the reference have 96 wells thus also anticipating the claim 18 different oligonucleotides limitation. See example 7 in column 12. Claims 23 and 24 and equivalents are included due to these claims being directed to product by process type subject matter which is not deemed to distinguish over the basic array claims subject matter. Fluorescent labels are cited in column 3, lines 37-43, as also in instant claim 75 as are radioactive practice in column 3, lines 56-64, as in instant claim 76.

OBVIOUSNESS DOUBLE PATENTING

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 17-99 are rejected under the judicially created doctrine of obviousnesstype double patenting as being unpatentable over claims 1-12 of U.S. Patent 6,054,270.

Art Unit: 1631

Although the conflicting claims are not identical, they are not patentably distinct from each other because the respective claim sets are drawn to arrays, methods of making same and analyzing same specifically citing impermeable supports, allelic variants a plurality of different oligonucleotides and methods standard in hybridization assays of using them including also computer implemented practice as well as densities cited in the respective specifications described as Dictionary terms for the arrays as respectively claimed.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

No claim is allowed.

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the Central PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CFR § 1.6(d)). The Central PTO Fax Center number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ardin Marschel, Ph.D., AU 1631 Supervisory Patent Examiner, whose telephone number is (571) 272-0718. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instrument Examiner, Tina Plunkett, whose telephone number is (571) 272-0549.

Art Unit: 1631

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

July 10, 2005

ARDIN H. MARSCHEL SUPERVISORY PATENT EXAMINER